Intermediate Risk References

#1

Abugharib, AE
External beam radiation therapy with or without low-dose-rate brachytherapy: analysis of favorable and unfavorable intermediate-risk prostate cancer patients.

Brachytherapy 2017;16(4):782-89

Find this article


#2

Abugharib, AE
External beam radiation therapy with or without low-dose-rate brachytherapy: analysis of favorable and unfavorable intermediate-risk prostate cancer patients.

Brachytherapy 2017;16(4):782-89

Find this article


#3

Aoun, F.
Predicitve factors associated with biochemical recurrence following radical prostatectomy for pathological T2 prostate cancer with negative surgical margins.

Scand J Urol 2017;51(1):20-26

Find this article


#4

Bahn, D
Targeted Cryoablation of the Prostate: 7_Year Outcomes in the Primary Treatment of Prostate Cancer

Urology 2002;60(2A):3-11

Find this article


#5

Bece, A
High-dose-rate brachytherapy boost for prostate cancer: Outcomes and genitourinary toxicity.

Brachytherapy 2015;14(5):670-76

Find this article


#6

Bittner, N
Primary causes of death after permanent prostate brachytherapy

IJROBP 2008;72(2):433-440

Find this article


#7

Bittner, N
Primary causes of death after permanent prostate brachytherapy

IJROBP 2008;72(2):433-440

Find this article


#8

Boorjian,S
Mayo Clinic Validation of the D'Amico Risk Group Classification for Predicting Survival…

J. Urology 2008;179():1354-1361

Find this article


#9

Bracci, S
Different outcomes among favourable and unfavourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy.

Radiat Oncol 2016;11():78

Find this article


#10

Bryant, C
Five-year biochemical results, toxicity, and patient-reported quality of life after delivery of dose-=escalated image-guided proton therapy for prostate cancer.

Urology 2015;95(1):422-34

Find this article


#11

Busch, J
Long-term oncological and continence outcomes after laparoscopic radical prostatectomy: a single-centre experience

BJU Int 2012;110(11):E985-90

Find this article


#12

Catton, CN
Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer

J Clin Oncol 2017;35(17):1884-90

Find this article


#13

Catton, CN
Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer

J Clin Oncol 2017;35(17):1884-90

Find this article


#14

Critz, F
10 Year disease free survival rates after simultaneous irradiation fro prostate cancer with a focus on calulation and methodology

J. Urology 2004;172():2232-2338

Find this article


#15

Critz, FA
25-year disease-free survival rate after irradiation for prostate cancer calculated with the prostat specific antigen definition of recurrences used for radical prostatectomy

J Urol 2013;189(3):878-83

Find this article


#16

Crouzet, S
Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncological outcomes and morbidity in 1002 patients

Eur Urol 2013;epub Apr 30():

Find this article


#17

Cury, FL
Single-fraction high-dose-rate brachytherapy and hypofractionated exteranl beam radiation therapy in the treatment of intermediate-risk prostate cancer- long term results

IJROBP 2012;82(4):14717-23

Find this article


#18

Dattoli, M
Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features

Cancer 2007;110(3):551-555

Find this article


#19

Dattoli, M
Long-Term Outcomes for Patients with Prostate Cancer Having Intermediate and High-Risk Disease, Treated with Combination External Irradiation and Brachytherapy

Journal of Oncology 2010;2010():Article ID 471375 6pgs.

Find this article


#20

Diaz, M
Oncological outcomes at 10 years following robotic radical prostatectomy

Eur Urol 2015;67(6):1168-76

Find this article


#21

Dearnaley, D
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Lancet Oncol 2016;17(8):1047-60

Find this article


#22

Demanes, D J
Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation

Am J. Clinical Oncology 2009;32(4):342-347

Find this article


#23

Fellin, G.
Low dose rate bachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series o 2237 patients from 11 institutions.

Br J Radiol 2016;89(1065):20150981

Find this article


#24

Fujimura, T
Robot-assisted radical prostectomy significntly reduced biochemical recurrence compared to retro pubic radical prostatectomy.

BMC Cancer 2017;17(1):454

Find this article


#25

Fujimura, T
Robot-assisted radical prostectomy significntly reduced biochemical recurrence compared to retro pubic radical prostatectomy.

BMC Cancer 2017;17(1):454

Find this article


#26

Galalae, R
Long-term outcome by risk factors using conformal high dose brachy boost with or without Neoadjuvant androgen suppression for localized prostate cancer

IJROBP 2004;58(4):1048-1055

Find this article


#27

Galalae, R
Hypofractionated Conformal HDR Brachytherapy in Hormone Naïve Men with Localized Prostate Cancer: Is Escalation to Very High Biologically Equivalent Beneficial in All Progonstic Risk Groups?

Strahlentherapie und Onkologie 2006;181():135-141

Find this article


#28

Ganzer, R
Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer.

BJU Int 2013;112(3):322-9

Find this article


#29

Genebes, C
Conventional versus automated implantation of loose seeds in prostate brachytherapy: analysis of dosimetric and clinical results

IJROBP 2013;87(4):651-58

Find this article


#30

Goy, BW
Treatment results of brachytherapy vs. external beam radiation therapy for intermediate-risk prostate cancer with 10-year followup.

Brachytherapy 2016;15(6):687-94

Find this article


#31

Hauswald, H.
High-dose-rate monotherapy for localized prostate cancer: 10-year results.

IJROBP 2016;94(4):667-74

Find this article


#32

Helou, J
High-dose-rate brachytherapy boost for intermediate-risk prostate cancer: long-term outcomes of two different treatment schedules and early biochemical…

Radiother Oncol 2015;115(1):84-89

Find this article


#33

Herbert, C
Outcomes following iodine-125 brachytherapy in patients with Gleason 7, intermediate risk prostate cancer: A population-based cohort study

Radiother Oncol 2012;103(2):228-32

Find this article


#34

Hinnen, K
Long-Term Biochemical and Survival Outcome of 921 Patients Treated with I125 Permanent Prostate Brachytherapy

IJROBP 2010;76(5):1433-1438

Find this article


#35

Ho, A
Radiation Dose Predicts for Biochemical Control in Intermediate-risk Prostaste Cancer Patients Treated with Low-dose rate Brachytherapy

IJROBP 2009;75(1):16-22

Find this article


#36

Ho, A
Radiation Dose Predicts for Biochemical Control in Intermediate-risk Prostaste Cancer Patients Treated with Low-dose rate Brachytherapy

IJROBP 2009;75(1):16-22

Find this article


#37

Hou, WH
Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation. Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation.

Asian J Androl 2016;epub 29():

Find this article


#38

Izard, M
Long-term outcome for prostate cancer using pseudo pulse-dosed rate brachytherapy, external beam radiotherapy, and hormones

Brachytherapy 2013;12(6):608-14

Find this article


#39

Jolnerovski, M
Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six-year outcomes and predictors of late toxicity.

Radiat Oncol 2017;12(1):99

Find this article


#40

Katz, A
Quality of life and toxicity after SBRT for organ-confined prostate cancer: 7 year study

Front Oncol 2014;4():301 (6 pgs.)

Find this article


#41

Katz, A
Predicting biochemical disease-free survival after prostate stereotactic body radiotherapy: risk-stratification and patterns of failure.

Front. Oncol 2016;6():168

Find this article


#42

Khor, R
Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs. external beam radiation therapy alone for prostate cancer

IJROBP 2013;85(3):1679-85

Find this article


#43

Khor, R
Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs. external beam radiation therapy alone for prostate cancer

IJROBP 2013;85(3):1679-85

Find this article


#44

Kittel, J
Long-term efficacy and toxicity of low-dose-rate 125-I prostate brachytherapy as monotherapy in low-, intermediate- and high-risk prostate cancer

IJROBP 2015;92(4):884-93

Find this article


#45

Klein, E
Outcomes For Intermediate Risk Prostate Cancer: Are There Advantage For Sugery, External Beam, or Brachytherapy

Urologic Oncology 2009;27():67-71

Find this article


#46

Klein, E
Outcomes For Intermediate Risk Prostate Cancer: Are There Advantage For Sugery, External Beam, or Brachytherapy

Urologic Oncology 2009;27():67-71

Find this article


#47

Klein, E
Outcomes For Intermediate Risk Prostate Cancer: Are There Advantage For Sugery, External Beam, or Brachytherapy

Urologic Oncology 2009;27():67-71

Find this article


#48

Kotecha, R
Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer

Brachytherapy 2013;12(1):44-49

Find this article


#49

Kuban, D
Long-Term Multi-Institutional Analysis of Stage T1-T2 Prostate Cancer Treated with Radiotherapy in the PSA Era

IJROBP 2003;57(4):915-928

Find this article


#50

Kupelian, P
Improved Biochemical Relapse-Free Survival With Increased Radiation Doses in Patients With Locaized Prostate Cancer: The Combined Experience of Nine Institutions in 1994 and 1995

IJROBP 2005;61(2):415-419

Find this article


#51

Kupelian,P
Radical Prostatectomy, External Beam Radiotherapy <72 Gy, External Beam Radiotherapy ?72 Gy, Permanent Seed Implantation, or Combined Seeds/External Beam Radiotherapy for Stage T1-T2 Prostate Cancer

IJROBP 2004;58(1):25-33

Find this article


#52

Kupelian,P
Radical Prostatectomy, External Beam Radiotherapy <72 Gy, External Beam Radiotherapy ?72 Gy, Permanent Seed Implantation, or Combined Seeds/External Beam Radiotherapy for Stage T1-T2 Prostate Cancer

IJROBP 2004;58(1):25-33

Find this article


#53

Kupelian,P
Radical Prostatectomy, External Beam Radiotherapy <72 Gy, External Beam Radiotherapy ?72 Gy, Permanent Seed Implantation, or Combined Seeds/External Beam Radiotherapy for Stage T1-T2 Prostate Cancer

IJROBP 2004;58(1):25-33

Find this article


#54

Kupelian,P
Radical Prostatectomy, External Beam Radiotherapy <72 Gy, External Beam Radiotherapy ?72 Gy, Permanent Seed Implantation, or Combined Seeds/External Beam Radiotherapy for Stage T1-T2 Prostate Cancer

IJROBP 2004;58(1):25-33

Find this article


#55

Lawton, C
Long-term results of an RTOG phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate

IJROBP 2012;82(5):e795-e801

Find this article


#56

Louis, AS
Oncologic outcomes following radical prostatectomy in the active surveillance era.

Can Urol Assoc J 2013;7(7,8):E475-80

Find this article


#57

Ludwig, MS
The role of androgen deprivation therapy on biochemical failure and distant metastisis in intermediate-risk prostate cancer: effects of radiation dose escalation.

BMC Cancer 2015;15():190(8 pgs)

Find this article


#58

Marina, O
Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients

Brachytherapy 2014;13(1):59-67

Find this article


#59

Marshall, R
Treatment outcomes and morbidity following definitive brachytherapy with or without external beam radiation for the treatment of localized prostate cancer: 20-year experience at Mount Sinai Medical Center

Urol Oncol 2013;32(1):38e1-7

Find this article


#60

Martin, A-G
Permanent Prostate Implant Using High Activity Seeds & Inverse Planning With Fast Simulated Annealing Algorithum: A 12-Year Canadian Experience

Int. J. Rad Onc/Bio 2007;67(2):334-341

Find this article


#61

McPartlin, AJ
Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external beam radiation therapy for localized prostate cancer.

Cancer 2016;122(16):2595-603

Find this article


#62

McPartlin, AJ
Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external beam radiation therapy for localized prostate cancer.

Cancer 2016;122(16):2595-603

Find this article


#63

Menon, M
Biochemical Recurrence Following Robot-assisted radical prostatectomy: analysis of 1384 patients with a median 5-year follow-up

Eur. Urol. 2010;58():838-46

Find this article


#64

Merrick, G
Prognostic Significance of perineural invasion on biochemical progression-free survival after prostate brachytherapy

J. Urology 2005;66(5):1048-1053

Find this article


#65

Merrick, G
Androgen deprivation therapy dose not impact cause specific overall survival after permanent prostate brachytherapy

IJROBP 2006;65(3):669-677

Find this article


#66

Merrick, G
Is supplemental external beam radiation therapy necessary for patients with higher risk prostate cancer treated with 103-Pd? Results of two prospective randomized trials.

Brachytherapy 2015;14(5):677-85

Find this article


#67

Merrick, G
Is supplemental external beam radiation therapy necessary for patients with higher risk prostate cancer treated with 103-Pd? Results of two prospective randomized trials.

Brachytherapy 2015;14(5):677-85

Find this article


#68

Merrick, G
(Fav.)Is supplemental external beam radiation therapy essentrial to maximize brachytherapy outocmes in patients with unfavorable intermediate-risk disease?

Brachytherapy 2016;15(1):79-84

Find this article


#69

Merrick, G
(Unfav.)Is supplemental external beam radiation therapy essentrial to maximize brachytherapy outocmes in patients with unfavorable intermediate-risk disease?

Brachytherapy 2016;15(1):79-84

Find this article


#70

Michalski, J
Clinical outcomes of patients treated with 3D conformal radaiation therapy (3D-CRT) for prostate cancer on RTOG 9406.

IJROBP 2012;83(3):e363-70

Find this article


#71

Mirhadi, AJ
Effect of long-term hormonal therapy (vs short-term hormonal therapy): a secondary analysis of intermediate-risk prostate cancer patients treated on NRG oncology TROG 9202.

IJROBP 2017;97(3):511-515

Find this article


#72

Morris, L
Does prostate-specifc antigen nadir predict longer-term outcomes of prostate cancer after neoadjuvant and adjuvant androgen deprivation therapy in conjunction with brachytherapy?

Brachytherapy 2015;14():322-28

Find this article


#73

Morris, WJ
Population-based 10-year oncological outcomes after low-dose-rate brachytherapy for low-risk and intermediate-risk prostate cancer

Cancer 2013;119(8):1537-46

Find this article


#74

Morris, WJ
Androgen Suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): An analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer.

IJROBP 2017;98(2):275-85

Find this article


#75

Morris, WJ
Androgen Suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): An analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer.

IJROBP 2017;98(2):275-85

Find this article


#76

Moyad, M
STATINS, ESPECIALLY ATORVASTATIN, MAY FAVORABLY INFLUENCE CLINICAL PRESENTATION AND BIOCHEMICAL PROGRESSION-FREE SURVIVAL AFTER BRACHYTHERAPY FOR CLINICALLY LOCALIZED PROSTATE CANCER

Urology 2005;66(6):1150-1154

Find this article


#77

Mullins, JK
The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary.

J Urol 2012;188(6):2205-10

Find this article


#78

Munro, NP
Outcomes for Gleason 7, intermediate risk, localized prostate cancer treated with iodine-125 monotherapy over 10 years.

Radiotherapy & Oncology 2010;96(1):34-37

Find this article


#79

Neto, O.B.
Hypofrationated radiation therapy for prostate cancer: the McGill University Health Center Experience

Cancer Radiother 2015;19(6,7):431-36

Find this article


#80

Ohashi, T
Outcomes following iodine-125 prostate brachytherapy with or without neoadjuvant androgen deprivation

Radiother & Oncol 2013;109():241-45

Find this article


#81

Patel, S.
High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.

Brachytherapy 2017;16(2):299-305

Find this article


#82

Phan, T
High dose rate brachytherapy as a boost for the treatment of localized prostate cancer

J. Urology 2007;177():123-127

Find this article


#83

Pollack, A
Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer

J Clin Oncol 2013;31(31):3860-68

Find this article


#84

Pickles, T
High-intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy.

Brachytherapy 2017;16(6):1101-05

Find this article


#85

Pickles, T
High-intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy.

Brachytherapy 2017;16(6):1101-05

Find this article


#86

Potters, l
12-Year Outcomes Following Permanent Prostate Brachytherapy in Patients With Clinically Localized Prostate Cancer

J. Urology 2005;173():1562-1566

Find this article


#87

Raziee, H
Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy.

Radiother & Oncol 2017;123(3):459-65

Find this article


#88

Raziee, H
Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy.

Radiother & Oncol 2017;123(3):459-65

Find this article


#89

Rossi, C. Jr.
Conformal proton beam radiation therapy for prostate cancer: Concepts and clinical results.

Community Oncology 2007;4():235-240

Find this article


#90

Sabolch, A
Gleason Pattern 5 is the Greatest Risk Factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation

IJROBP 2011;81(4):e351-60

Find this article


#91

Schreiber, D
Clincal and biochemical outcomes for men undergoing radical prostatectomy or radiation therapy for localized prostate cancer.

Raidat Oncol 2015;33(1):21-28

Find this article


#92

Schreiber, D
Clincal and biochemical outcomes for men undergoing radical prostatectomy or radiation therapy for localized prostate cancer.

Raidat Oncol 2015;33(1):21-28

Find this article


#93

Sekiguchi, A
125 Iodine monotherapy for Japanese men with low-and intermediate-risk prostate cancer: outcomes after 5-years of follow-up.

J Radiat Res. 2014;55(2):328-33

Find this article


#94

Shiraishi, Y
A dose-response analysis of biochemical control outcomes after 125-I monotherapy for patients with favorable-risk prostate cancer

IJROBP 2014;90(5):1069-75

Find this article


#95

Soares, R
Minimum 5-year follow-up of 1138 consecutive laparoscopic radical prostatectomies.

BJU Int. 2015;115():546-53

Find this article


#96

Sooriakumaran, P
Biochemical Recurrence After Robot-assisted Radical Prostatectomy in a European Single-centre Cohort with a Minimum Follow-up Time of 5 Years

Eur Urol 2012;62(5):768-74

Find this article


#97

Spratt, D
Comparison of high-dose (86.4 Gy) IMRT vs combo brachytherapy and IMRT for intermediate-risk prostate cancer

BJU Int 2014;114(3):360-67

Find this article


#98

Spratt, D
Comparison of high-dose (86.4 Gy) IMRT vs combo brachytherapy and IMRT for intermediate-risk prostate cancer

BJU Int 2014;114(3):360-67

Find this article


#99

Spratt, DE
Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer

IJROBP 2013;85(3):686-92

Find this article


#100

Stone, N.
Local control Following Permanent Prostate Brachytherapy: Effect of High Biologically Effective Dose on Biopsy Results and Oncologic Outcomes

IJROBP 2010;76(2):355-360

Find this article


#101

Surapaneni, A
Radiation therapy for clinically localized prostate cancer: Long-term results of 469 patients from a single institution in the era of dose escalation.

J Ca Res Ther 2014;10(4):951-56

Find this article


#102

Tabata, R
Do androgen deprivation and the biologically equivalent dose matter in low-dose-rate brachytherapy for intermediate-risk prostate cancer?

Cancer Med. 2016;5(9):2314-22

Find this article


#103

Taira, A
Natural History of Clinically Staged Low- and Intermediate Risk Prostate Cancear Treated With Monotherapeutic Permanent Interstitial Brachytherapy

IJROBP 2010;76(2):349-354

Find this article


#104

Thames, H
Low/ Int Increasing External Inter Beam Dose for T1-T2 High Inter Prostate Cancer: Effect on Risk Groups

Int. J. Rad Onc/Bio 2006;65(4):975-981

Find this article


#105

Thames, H
Mid/ Increasing External Beam Dose for T1-T2 Prostate Cancer: Effect on Risk Groups

Int. J. Rad Onc/Bio 2006;65(4):975-981

Find this article


#106

Thames, H
Hi/ Increasing External Beam Dose for T1-T2 Prostate Cancer: Effect on Risk Groups

Int. J. Rad Onc/Bio 2006;65(4):975-981

Find this article


#107

Thüroff, S
Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years

J Urol 2013;190(2):702-10

Find this article


#108

Tran, A
Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial Brachytherapy monotherapy

Radiotherapy & Oncol 2013;109(2):235-40

Find this article


#109

Uchida
(Group #1)Improved Outcomes with advancements in high intensity focused ultrasound devices for the treatment of localized prostate cancer.

J Urol 2015;193(1):103-10

Find this article


#110

Uchida
(Group #2)Improved Outcomes with advancements in high intensity focused ultrasound devices for the treatment of localized prostate cancer.

J Urol 2015;193(1):103-10

Find this article


#111

Vassil, AD
Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation, or permanent seed implantation

Urology 2010;76(5):1251-57

Find this article


#112

Vassil, AD
Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation, or permanent seed implantation

Urology 2010;76(5):1251-57

Find this article


#113

Vassil, AD
Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation, or permanent seed implantation

Urology 2010;76(5):1251-57

Find this article


#114

Vigneault, E
High-dose-rate brachytherapy boost for prostate cancer treatment: different combinations of hypofractionated regimens and clinical outcomes.

Radiother Oncol 2017;124(1):49-55

Find this article


#115

Vora, S
Nine-year outcome and toxicity in patients treated with IMRT for localized prostate cancer

J Urol 2013;In Press(02/06/2013 00:00:00):

Find this article


#116

Weller, M
Adjuvant versus neoadjuvant androgen deprivation with radiotherapy for prostate cancer: does sequencing matter?

Clin Genitourin Ca 2014;epub Dec 31():

Find this article


#117

Yamada, Y
Permanent prostate brachytherapy and short-term androgen deprivation for intermediate-risk prostate cancer in Japanese men: outcome and toxicity.

Brachytherapy 2015;14(2):118-23

Find this article


#118

Yaxley, JW
Long-term outcomes of high-dose-rate brachytherapy for intermediate- and high-risk prostate cancer with a median follow-up of 10 years.

BJU Int 2016;epub Sept 15():

Find this article


#119

Yorozu, A
Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as predicted in Japan: Outcomes of 1300 patients

Brachytherapy 2015;14(2):111-17

Find this article


#120

Yoshioka, Y.
Nationwide, multicenter, retrospecitve study on high-dose-rate brachytherapy as monotherapy for prostate cancer.

IJROBP 2017;97(5):952-61

Find this article


#121

Zelefsky, M
Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation

IJROBP 2007;67(2):327-333

Find this article


#122

Zelefsky, M
Long Term Outcome of High Dose Intensity Modulated Radiation Therapy for Patients With Clinically Localized Prostate Cancer

J. Urology 2006;176():1415-1419

Find this article


#123

Zumsteg, Z
(Fav. Risk) A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy

Eur Urol 2013;64(6):895-902

Find this article


#124

Zumsteg, Z
(Unfav. Risk) A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy

Eur Urol 2013;64(6):895-902

Find this article


#125

Zumsteg, Z
(+ ADT)Short-term androgen-deprivation therapy improves prostate cancer-specific mortality on intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy

IJROBP 2013;85(4):1012-7

Find this article


#126

Zumsteg, Z
(-ADT)Short-term androgen-deprivation therapy improves prostate cancer-specific mortality on intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy

IJROBP 2013;85(4):1012-7

Find this article